Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/19/2018 |
| Start Date: | March 2014 |
| End Date: | October 2018 |
Contrast-enhanced magnetic resonance imaging (CE-MRI) is now established as the most accurate
non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high
sensitivity because the intravenous MR contrast agent highlights regions with increased
vascularization and vascular permeability compared to normal breast tissues and benign
lesions.
non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high
sensitivity because the intravenous MR contrast agent highlights regions with increased
vascularization and vascular permeability compared to normal breast tissues and benign
lesions.
Contrast-enhanced magnetic resonance imaging (CE-MRI) is now established as the most accurate
non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high
sensitivity because the intravenous MR contrast agent highlights regions with increased
vascularization and vascular permeability compared to normal breast tissues and benign
lesions. While research continues on improving the specificity of CE-MRI, several other MR
techniques that do not require an exogenous contrast agent have been shown to provide
valuable information that can improve the characterization of breast cancers. These
techniques include magnetic resonance spectroscopy (MRS), diffusion-weighted imaging, and
water T2 relaxometry. The long-term goal of this study is to develop these techniques to
produce quantitative MR-based biomarkers that can be used to supplement or possibly supplant
the information provided by CE-MRI. This project seeks to facilitate the advancement of these
advanced, non-contrast techniques. This study uses a piggyback design, in which subjects who
are already scheduled to receive a CE-MRI study are invited to receive an additional 10-20
minutes of scanning to help develop these novel methods. This efficient design allows for the
refinement and assessment of these new techniques with a minimum of risk and inconvenience to
the patient. With these proposed improvements, these techniques may lead to quantitative
biomarkers that can guide critical clinical questions in treatment response, diagnosis,
staging, and high-risk screening of breast cancer.
non-invasive imaging modality for characterizing breast cancer. CE-MRI has a very high
sensitivity because the intravenous MR contrast agent highlights regions with increased
vascularization and vascular permeability compared to normal breast tissues and benign
lesions. While research continues on improving the specificity of CE-MRI, several other MR
techniques that do not require an exogenous contrast agent have been shown to provide
valuable information that can improve the characterization of breast cancers. These
techniques include magnetic resonance spectroscopy (MRS), diffusion-weighted imaging, and
water T2 relaxometry. The long-term goal of this study is to develop these techniques to
produce quantitative MR-based biomarkers that can be used to supplement or possibly supplant
the information provided by CE-MRI. This project seeks to facilitate the advancement of these
advanced, non-contrast techniques. This study uses a piggyback design, in which subjects who
are already scheduled to receive a CE-MRI study are invited to receive an additional 10-20
minutes of scanning to help develop these novel methods. This efficient design allows for the
refinement and assessment of these new techniques with a minimum of risk and inconvenience to
the patient. With these proposed improvements, these techniques may lead to quantitative
biomarkers that can guide critical clinical questions in treatment response, diagnosis,
staging, and high-risk screening of breast cancer.
Inclusion Criteria:
- Women scheduled and eligible to receive a contrast-enhanced breast MRI at the UMN
Center for Clinical Imaging Research for either standard clinical care, or
participation in the ISPY2/ACRIN6698 clinical research study
- Age 18 years or older
- Ability to read and understand English
- Ability to provide written informed consent
Exclusion Criteria:
- Subjects who are unlikely to tolerate the longer MRI scanning duration. This may
include, history of discomfort during MRI scanning, anxiety, or claustrophobia
We found this trial at
1
site
Click here to add this to my saved trials
